• Recursion Pharmaceuticals’ stock rises 8% in pre-market to $5.08 after positive trial results. • The Phase 1B/2 TUPELO trial indicates significant reductions in polyp burden for REC-4881, enhancing ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Brendan Fraser and Rachel Weisz are reuniting for another “Mummy” adventure. Filmmakers Matt Bettinelli-Olpin and Tyler Gillett, who call themselves Radio Silence, are set to direct the fourth ...

Quick starts from a rich Draft class shakes up the presumed order as VJ Edgecombe and Cedric Coward shine brightest. Steve Aschburner Sixers rookie VJ Edgecombe ranks No. 1 among rookies and No. 30 ...

The chefs behind two of Des Moines’ beloved French restaurants return, launching a new restaurant with an old name. Bistro Montage is making a comeback with chefs David Baruthio and Enosh Kelley ...

SpaceX teased the next-generation vehicle that could reach the moon and Mars during its live webcast of a Starship mission known as flight 11. Starship is regarded as the world's largest and most ...

Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Explore the increasingly bizarre differences between Minecraft's Java and Bedrock editions. What makes these versions so unique? Iranian gunboats unsuccessfully attempt to board US oil tanker as Trump ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...